(CercleFinance.com) – Advicenne announced on Tuesday a 13% increase in its sales for the 2022 financial year, in particular thanks to a significant acceleration in its growth in the second half.
The pharmaceutical company specializing in the treatment of rare kidney diseases published this morning annual revenues of 3.7 million euros, compared with 3.3 million euros for the previous year.
The annual growth comes mainly from sales of Sibnayal, which amount to 1.4 million euros in 2022, up 40% compared to the previous financial year.
Sibnayal, a fixed combination of potassium citrate and potassium bicarbonate, is indicated for the treatment of distal renal tubular acidosis (dRTA) in adults, adolescents and children.
In its statement, Advicenne notes that the second half of 2022 saw a marked acceleration in the growth of Sibnayal sales, which jumped 70% over the second half of the year thanks to the live launch in Great Britain.
The company also claims to have benefited from the taking effect of various partnerships concluded in Europe and from the development of the therapeutic management of patients suffering from dRTA in France.
In a reaction note, analysts at Invest Securities point to annual turnover which evolves ‘still at modest levels’, which resulted in a decline of more than 6% in the action on Tuesday at the end of Paris stock exchange.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Are you following this action?
Receive all the information about ADVICENNE in real time: